Pharsight

Drugs that contain Betrixaban

1. Bevyxxa patents expiration

BEVYXXA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7598276 PORTOLA PHARMS INC Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Nov, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9555023 PORTOLA PHARMS INC Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Nov, 2026

(2 years from now)

US8557852 PORTOLA PHARMS INC Methods of using crystalline forms of a salt of a factor Xa inhibitor
Sep, 2028

(4 years from now)

US8987463 PORTOLA PHARMS INC Methods of synthesizing factor Xa inhibitors
Dec, 2030

(6 years from now)

US8404724 PORTOLA PHARMS INC Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Mar, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 23, 2022

NCE-1 date: 2021-06-23

Market Authorisation Date: 23 June, 2017

Treatment: Prophylaxis of pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Prophylaxis of venous thrombosis; Inhibiting coagulation

Dosage: CAPSULE;ORAL

More Information on Dosage

BEVYXXA family patents

Family Patents